		2022 \$ Dr	2022	2021 \$ Dr	2021
		\$ Dr	\$ Cr	\$ Dr	\$ Cr
	Income				
0575	Interest received		1.26		8.07
0600	Profit on sale of assets				786.75
0716.04	Employers contributions				20.00
0852	Distribution from trusts		82,131.92		56,485.72
0880	Units in managed funds	131,088.77			134,682.06
	Expenses				
1510	Accountancy	1,075.25		910.25	
1535	Audit fees	330.00		330.00	
1545	Bank fees & charges	2.10		2.10	
1685	Filing fees	259.00		259.00	
1798	Management fees	5,780.89		5,772.01	
1998.03	Income tax expense - Earnings			804.62	
1998.04	Income tax expense - Earnings			680.68	
1999.03	Income tax expense - Contribution	599.39			
<u>1999.04</u>	Income tax expense - Contribution	502.51			
	Current Assets				
2000	Cash at bank - Voyage	16,861.93		9,500.00	
2001	Cash at bank - Bendigo *527	9,433.27		8,091.32	
	Non Current Assets				
2640.02	Trust - Blackrock Balanced	263,234.65		323,242.96	
2640.03	Trusts - Perpetual	148,272.87		157,381.83	
2640.04	Trusts - MLC Horizon 4	179,838.75		207,500.52	
2640.06	Trusts - Fidelity Aust	128,558.29		146,174.20	
2640.07	Trusts - Pendal Imputation	174,059.21		182,082.91	
2640.08	Trusts - Vanguard Cons	65,632.36		74,302.48	

H & A Products Pty Ltd Superannuation Fund ABN 43 402 702 458 Comparative Trial Balance as at 30 June 2022

These financial statements are unaudited. They must be read in conjunction with the attached Accountant's Compilation Report and Notes which form part of these financial statements.

		2022 \$ Dr	2022 \$ Cr	2021 \$ Dr	2021 \$ Cr
	Current Liabilities				
3325	Taxation	7,888.46		3,008.30	
	Equity				
4000.01	Opening balance - Members fund		476,292.18		426,559.30
4000.02	Opening balance - Members fund		451,444.49		405,624.73
4000.03	Opening balance - Members fund		128,202.47		108,690.54
4000.04	Opening balance - Members fund		55,345.38		47,186.01
4080.01	Benefits paid	30,000.00		30,000.00	
4080.02	Benefits paid	30,000.00		30,000.00	
		1,193,417.70	1,193,417.70	1,180,043.18	1,180,043.18
	Net Loss	57,504.73			183,223.94

H & A Products Pty Ltd Superannuation Fund ABN 43 402 702 458 Comparative Trial Balance as at 30 June 2022